Trial NCT05303584
Publication Tang R, Lancet Resp Med, 2023
Primary outcome on the report: 1. Incidence of adverse reactions occurring within 28 days after the fourth dose. 2. Geometric mean titres (GMTs) for neutralizing antibodies against the live SARS-CoV-2 virus at day 28.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.